Today, we have the privilege of speaking with Andrew, a distinguished leader with over 15 years of international experience in marketing, commercial excellence, and business strategy. Throughout his career, he has led large teams at top pharmaceutical and medical device companies, including Novartis, Terumo, and Penumbra Inc. Andrew is a proud graduate of the IGNITE Program at Stanford Graduate School of Business and has also studied at several other prestigious international business schools. His expertise and journey in medical innovation make him a key voice in understanding the challenges and opportunities within the industry.
Andrew Ortega-Verdaguer, IntelVasc Inc.
Newsletter
Get the Global Trial Accelerators™ newsletter
Practical insights on first-in-human and early feasibility trials across medtech, biotech/biopharma and radiopharma, in your inbox.
Free. Unsubscribe anytime. See the bioaccess® Privacy Policy (opens in a new tab) and the newsletter platform's Terms of Service (opens in a new tab).
Recent Episodes
- Varun Kalaiarasan, PhD Researcher at University of Cincinnati
- Ryan Beal, Chief Executive Officer at Dyve Biosciences
- Sandi Schaible, Founder & President at Bonded in Science
- Gennaro Maida, CEO and Founder at Denovo Innovations Group
- Benjamin Holmes, Chief Executive Officer at Nanochon
- Allison Komiyama, CEO and Founder at Bluestocking Health, LLC
- Daniel Zequeto, Founder & CEO at ODC Life Sciences
- Satabhisa Mukhopadhyay, Founder & Chief Scientist at 4D Path Inc
- Deborah Morley, Director CV Strategy and Delivery at RQM+
- See all →